UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 7.730

Sortiert nach

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

The Lancet (British edition), 2015-09, Vol.386 (9999), p.1156-1164

2015

Link zum Volltext

Verfügbarkeit prüfen

A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting

International journal of pharmaceutics, 2012-02, Vol.423 (1), p.16-25

2012

Link zum Volltext

Verfügbarkeit prüfen

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

The lancet oncology, 2020-11, Vol.21 (11), p.1423-1432

2020

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

The Lancet (British edition), 2019-01, Vol.393 (10168), p.229-240

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3109-3117

2021

Link zum Volltext

Verfügbarkeit prüfen

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Journal of clinical oncology, 2019-04, Vol.37 (12), p.984-991

2019

Link zum Volltext

Verfügbarkeit prüfen

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

The Lancet (British edition), 2019-12, Vol.394 (10216), p.2271-2281

2019

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Journal of clinical oncology, 2014-05, Vol.32 (13), p.1302-1308

2014

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1397-1410

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial

The lancet oncology, 2018-08, Vol.19 (8), p.1027-1039

2018

Link zum Volltext

Verfügbarkeit prüfen

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)

Journal of clinical oncology, 2020-03, Vol.38 (8), p.804-814

2020

Link zum Volltext

Verfügbarkeit prüfen

A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery

Journal of controlled release, 2017-10, Vol.264, p.102-111

2017

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Journal of clinical oncology, 2021-11, Vol.39 (33), p.3671-3681

2021

Link zum Volltext

Verfügbarkeit prüfen

Graphene quantum dots for cancer targeted drug delivery

International journal of pharmaceutics, 2017-02, Vol.518 (1-2), p.185-192

2017

Link zum Volltext

Verfügbarkeit prüfen

A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy

Biomaterials, 2014-02, Vol.35 (7), p.2383-2390

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1049-1060

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 7.730

Suche als RSS-Feed

Aktive Filter

ThemaCisplatin - Administration & Dosage

ThemaPharmacology. Drug Treatments

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7.336)
Mit Volltextzugriff
(5.962)

Publikationsform

Artikel
(7.729)
magazinearticle
(1)

Sprache

11 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Doxorubicin - Administration & Dosage
(6.610)
Humans
(6.563)
Science & Technology
(5.967)
Life Sciences & Biomedicine
(5.274)
Female
(4.193)
Male
(3.128)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3.001)
Middle Aged
(2.858)
Oncology
(2.621)
Adult
(2.313)
Cyclophosphamide - Administration & Dosage
(2.248)
Aged
(2.180)
Doxorubicin
(2.010)
Vincristine - Administration & Dosage
(1.901)
Animals
(1.890)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(1.424)
Antibiotics, Antineoplastic - Administration & Dosage
(1.307)
Chemotherapy
(1.259)
Prednisone - Administration & Dosage
(1.188)
Treatment Outcome
(1.146)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(33)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)

A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Graphene quantum dots for cancer targeted drug delivery

A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816

Aktive Filter

Suchergebnisse filtern